磷酸化tau水平变化与早期阿尔茨海默病认知障碍严重程度的关联
本研究基于挪威DDI和加拿大PREVENT-AD两个独立队列,评估临床前阿尔茨海默病中血浆与脑脊液p-tau水平与认知障碍及未来记忆下降的关系。结果显示血浆p-tau217在A+个体中与认知状态一致,且与未来记忆下降相关,而p-tau181和p-tau231关联较弱。
要点
- 血浆p-tau217识别A+参与者AUC为0.85,与脑脊液p-tau217中度相关(rho=0.65)。
- 血浆p-tau217在MCI A+中诊断准确性(AUC 0.89)高于CN A+(AUC 0.79)。
- 仅血浆p-tau217与未来记忆下降相关(β=0.05,p<0.05),所有脑脊液p-tau标志物均相关。
核心结论
- 血浆p-tau217在A+个体中与认知状态一致,并反映脑脊液生物标志物异常,具有诊断和预后价值。
研究设计与样本
- 纵向观察性研究,纳入挪威DDI队列(n=431)和加拿大PREVENT-AD队列(n=190)的临床前AD病例和对照。
主要发现
- DDI中血浆p-tau217识别A+的AUC为0.85,与脑脊液p-tau217相关性rho=0.65(p<0.001)。
- 血浆p-tau217在MCI A+中AUC为0.89,高于CN A+的0.79(p<0.05);在A+/T+中AUC为0.88,高于A+/T-的0.78(p<0.05)。
- p-tau181和p-tau231的脑脊液-血浆相关性较弱(rho=0.47和0.32,p<0.001),且与A+个体认知状态关联较弱。
- A+ MCI较A+ CN的血浆p-tau217更高(p<0.001),在PREVENT-AD中得到验证。
- 仅血浆p-tau217与未来记忆下降相关(β=0.05,p<0.05),所有脑脊液p-tau标志物均与未来记忆下降相关。
临床怎么用
- 血浆p-tau217可用于A+个体的认知状态评估和预后判断,尤其在脑脊液分析或PET不可及时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Aligning biomarker evidence with clinical presentation in early Alzheimer disease (AD) is essential for improving diagnosis, prognosis, and interventions. This study evaluates the relationship between cognitive impairment, future decline, and phosphorylated tau levels in plasma and CSF in predementia AD. METHODS: This longitudinal observational study included predementia cases and controls from 2 independent cohorts: the Norwegian Dementia Disease Initiation (DDI) and Canadian Pre-Symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD). In DDI, cognitively normal (CN) and mild cognitive impairment (MCI) cases were classified using CSF Aβ42/40 ratio (A) and p-tau181 (T), whereas classification in PREVENT-AD (A) was based on amyloid PET scans. In DDI, we assessed CSF-plasma correlations for p-tau181, p-tau217, and p-tau231. Diagnostic accuracies were evaluated through receiver operating characteristic analyses. Linear mixed models evaluated p-tau associations with future memory decline. Between-group differences in plasma p-tau217 were assessed in both cohorts. RESULTS: In DDI (n = 431), participants were classified as CN A-/T- (n = 169), A+/T- (CN = 26, MCI = 24), A+/T+ (CN = 40, MCI = 105), and A-/T+ (CN = 34, MCI = 33), with a mean age of 64.1 years and 55.9% female. In PREVENT-AD (n = 190), participants were categorized as CN A- (n = 118), CN A+ (n = 49), and MCI A+ (n = 21), with a mean age of 67.8 years and 72.6% female. In DDI, plasma p-tau217 showed high accuracy in identifying A+ participants (areas under the curve [AUC]: 0.85) and a moderate correlation with CSF p-tau217 (rho = 0.65, p < 0.001). Diagnostic accuracy of plasma p-tau217 was greater in MCI A+ (AUC: 0.89) than in CN A+ (AUC: 0.79, p < 0.05) and in A+/T+ (AUC: 0.88) vs A+/T- (AUC: 0.78, p < 0.05). p-Tau181 and p-tau231 had weaker CSF-plasma correlations (rho = 0.47 and rho = 0.32, p < 0.001) and were less associated with cognitive status in A+ individuals. Higher plasma p-tau217 in A+ MCI vs A+ CN individuals (p < 0.001) was confirmed in PREVENT-AD. All CSF p-tau markers, but only plasma p-tau217, were associated with future memory decline (β = 0.05, p < 0.05). DISCUSSION: Our findings suggest that, unlike p-tau181 and p-tau231, plasma p-tau217 consistently aligns with cognitive status in A+ individuals and better reflects CSF biomarker abnormalities, reducing discrepancies between clinical and biochemical findings. Its association with baseline and future memory decline highlights its diagnostic and prognostic value, particularly when CSF analysis or PET is unavailable.
引用
- Gonzalez-Ortiz F, Kirsebom BE, Yakoub Y, et al. Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease. Neurology. 2025. PMID: 40373247. doi:10.1212/WNL.0000000000213676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。